Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.

@article{Kachnic2011LongitudinalQA,
  title={Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.},
  author={Lisa A. Kachnic and Kathryn M. S. Winter and Todd H. Wasserman and David Paul Kelsen and Robert J. Ginsberg and Thomas Michael Pisansky and James A. Martenson and Ritsuko Komaki and Gordon S Okawara and Seth A Rosenthal and Christopher G Willett and Bruce D. Minsky},
  journal={Gastrointestinal cancer research : GCR},
  year={2011},
  volume={4 2},
  pages={
          45-52
        }
}
BACKGROUND Longitudinal quality of life (QoL) was compared for patients with esophageal cancer receiving definitive chemoradiotherapy (CRT) with conventional-dose (CD) vs. high-dose (HD) radiotherapy as used in the RTOG phase III 94-05 trial (Intergroup 0123). METHODS Between June 12, 1995, and July 1, 1999, 236 patients with cT1-4NxM0 esophageal cancer were randomized to CD CRT (50.4 Gy and concurrent 5-fluorouracil and cisplatin) vs. HD CRT (64.8 Gy and the same chemotherapy). QoL was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS